IGI Logo

Granules India is currently trading at Rs. 288.30, up by 2.75 points or 0.96% from its previous closing of Rs. 285.55 on the BSE.

The scrip opened at Rs. 285.75 and has touched a high and low of Rs. 289.00 and Rs. 285.75 respectively. So far 38097 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 289.00 and Rs. 275.30 respectively. The current market cap of the company is Rs. 6986.56 crore.

The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.93% and 29.05% respectively.

Granules India has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets USP, 250 mg, 500 mg, 750 mg, and 1,000 mg. bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keppra Tablets of UCB, Inc. (UCB).

Levetiracetam Tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and infants of age 1 month and older children with epilepsy; Myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy; Primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. 

Granules now has a total of 58 ANDA approvals from USFDA (56 Final approvals and 2 tentative approvals).The current annual U.S. market for Levetiracetam Tablets is around $247 million, according to MAT March 2023, IQVIA/IMS Health.  

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).